Pacific Biosciences of California (PACB) reported $39.77 million in revenue for the quarter ended June 2025, representing a year-over-year increase of 10.4%. EPS of -$0.13 for the same period compares to -$0.20 a year ago.
The reported revenue represents a surprise of +9.06% over the Zacks Consensus Estimate of $36.46 million. With the consensus EPS estimate being -$0.18, the EPS surprise was +27.78%.
While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.
Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.
Here is how Pacific Biosciences performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
- Revenue- Product- Instrument: $14.15 million compared to the $10.9 million average estimate based on three analysts. The reported number represents a change of -3.7% year over year.
- Revenue- Product: $33.08 million compared to the $31.18 million average estimate based on three analysts. The reported number represents a change of +4.2% year over year.
- Revenue- Service and other: $6.68 million versus $5.09 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +56.6% change.
- Revenue- Product- Consumable: $18.93 million versus the three-analyst average estimate of $20.29 million. The reported number represents a year-over-year change of +11.4%.
View all Key Company Metrics for Pacific Biosciences here>>>
Shares of Pacific Biosciences have returned -6.8% over the past month versus the Zacks S&P 500 composite's +1.2% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Pacific Biosciences of California, Inc. (PACB): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
